A study in the scientific journal The Lancet shows that half of all global cancer deaths are due to life style-related risk factors such as smoking and alcohol use.
Polish cancer drug developer, Ryvu Therapeutics, has received €22m funding from the European Investment Bank via its venture debt instrument.
Avantium and AmBev, part of AB InBev Group, have inked an agreement on PEF for soft drink bottles.
With a Series A funding of CHF 30m from Versant Ventures, Vector Biopharma AG set out to solve several of the current gene delivery problems.
Swiss-headquarterd Novartis AG has reported two cases of fatal liver failure after treatment with the gene therapy Zolgensma.
Azenta Inc has entered into an agreement to acquire B Medical Systems S.á r.l. and its subsidiaries for €410m.
Sartorius Stedim Biotech has purchased the world’s largest human albumin producer Albumedix to broaden its product portfolio in animal-free cell media and to stabilise protein drugs.
As Genmab’s Hexabody tumour antibody platform is advancing, BioNTech has secured a licence in the field of immunotherapy to co-develop antibodies on 50:50 base.
British antifungal developer F2G Ltd has announced a $70mn financing round to push development of its late-stage compound olorofilm.
Sosei Heptares and AbbVie have inked a multi-target licence option drug discovery agreement in neurology.